GSK 692342
Alternative Names: 692342; GSK M72; GSK-692342; M72/AS01E; Mtb72F/AS02A; Recombinant-tuberculosis-vaccine-GSK; SB-692342; Tuberculosis-vaccine-Aeras/GSK; Tuberculosis-vaccine-GSK; Tuberculosis-vaccine-Mtb72f/AS02A; Tuberculosis-vaccine-recombinant-fusion-protein-Mtb72f/AS02ALatest Information Update: 01 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Recombinant fusion proteins; Synthetic vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Tuberculosis
Most Recent Events
- 03 Sep 2021 No development reported - Phase-II for Tuberculosis in Kenya (IM)
- 03 Sep 2021 No development reported - Phase-II for Tuberculosis in Zambia (IM)
- 23 Sep 2020 Bill & Melinda Gates Medical Research Institute plans a phase II MESA-TB trial for Tuberculosis (Prevention, In adolescents, In adults) in South Africa (NCT04556981)